A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer|Solid Tumor|Melanoma|Carcinoma|Sarcoma|Lung Cancer|Prostate Cancer|Breast Cancer|Colo-rectal Cancer|Uterine Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Thyroid Cancer|Ovarian Cancer|Kidney Cancer|Head and Neck Cancer
Interventions: DRUG: KVA12123 - Dose Escalation|DRUG: KVA12123 Plus Pembrolizumab - Dose Escalation|DRUG: KVA12123 - Dose Expansion|DRUG: KVA12123 Plus Pembrolizumab - Dose Expansion
Sponsor: Kineta Inc.
Collaborators: Merck Sharp & Dohme LLC